Diane 35 is a prescription hormonal tablet for women with androgen-dependent conditions such as severe acne, unwanted facial or body hair, and related menstrual symptoms. Its combined hormonal action…
Diane 35 is a prescription hormonal tablet for women with androgen-dependent conditions such as severe acne, unwanted facial or body hair, and related menstrual symptoms. Its combined hormonal action reduces androgen effects while supporting more predictable ovarian hormone activity.
Diane 35 belongs to the combined anti-androgenic hormonal treatment category. It is prescribed for women whose acne, excess hair growth, or other androgen-related symptoms require more than topical treatment or cosmetic care. The product is supplied as tablets.
Diane 35 belongs to the combined anti-androgenic hormonal treatment category. It is prescribed for women whose acne, excess hair growth, or other androgen-related symptoms require more than topical treatment or cosmetic care. In New Zealand, prescription status and clinical use are governed through the national medicines framework overseen by Medsafe.
The product is supplied as tablets. The exact regimen for the selected strength must be confirmed with a healthcare professional before starting.
Diane 35 is associated with the anti-androgen and oestrogen combination of cyproterone acetate and ethinylestradiol. Cyproterone acetate reduces the biological effect of androgens, while ethinylestradiol contributes oestrogenic activity and suppresses ovarian androgen production.
The two components act through different but complementary pathways. This combination explains why Diane 35 may be prescribed for androgen-dependent skin and hair symptoms rather than for acne unrelated to hormonal activity. Regulatory information for cyproterone-containing combined hormonal products describes both therapeutic benefits and important thromboembolic precautions [1].
A practical point is easy to miss: improvement in oiliness or facial hair is gradual. A tablet taken for a few days will not reverse an established hair-growth cycle or rapidly clear inflammatory acne.
Androgens act by binding to androgen receptors in tissues such as the skin and hair follicles. When androgen signalling is excessive, sebaceous glands may produce more sebum and hair follicles may produce thicker, darker hair.
Cyproterone acetate blocks androgen receptors. It also reduces androgen activity through effects on ovarian and adrenal androgen pathways. The result is less stimulation of androgen-sensitive skin and hair follicles.
Ethinylestradiol provides oestrogenic feedback to the hypothalamic-pituitary-ovarian axis. This reduces gonadotropin stimulation of the ovaries and can lower ovarian androgen production. It also increases hepatic production of sex hormone-binding globulin, which binds circulating testosterone and reduces the proportion available to enter tissues.
The clinical result is not an immediate hormone “reset.” Sebum production may take several weeks to settle, while hirsutism responds slowly because existing hairs continue through their normal growth cycle. Peer-reviewed reviews indexed in PubMed and guidance from NICE describe this delayed response as a consequence of follicular biology rather than a sign that treatment has failed [3].
Diane 35 differs from a skin-only treatment because it acts systemically. That can help when acne or hirsutism is driven by hormonal activity, but systemic exposure also creates risks that do not apply to a topical cream or wash.
Diane 35 is prescribed for women with moderate-to-severe androgen-dependent acne, hirsutism, or other signs of androgenization when hormonal treatment is clinically appropriate. Androgens are hormones that can increase sebaceous-gland activity and stimulate coarse hair growth in androgen-sensitive areas.
Common clinical contexts include:
Diane 35 does not treat every form of acne or every cause of irregular periods. A clinician usually considers the pattern of symptoms, menstrual history, blood pressure, migraine history, smoking status, body weight, family history, and previous hormonal treatment before prescribing it. Guidance from the EMA describes cyproterone/ethinylestradiol products as treatments for androgen-dependent conditions, with use limited to appropriate clinical situations [2].
For PCOS, Diane 35 may improve acne, hirsutism, and cycle predictability, but it does not remove the underlying metabolic features of PCOS. Blood-sugar problems, sleep apnoea, weight changes, and fertility planning require separate management.
Several avoidable errors reduce treatment reliability or increase risk:
The following conditions require exclusion or specialist assessment before treatment:
Interactions require a medication review. Enzyme-inducing medicines, including some treatments for epilepsy, tuberculosis, and HIV, can reduce hormonal reliability. Some herbal products, including St John’s wort, may also alter hormone metabolism. Certain hepatitis C antiviral combinations can affect hormone exposure. The interaction list should include prescription medicines, over-the-counter products, and supplements.
Diane 35 is not appropriate when a known contraindication applies.
NOT for you if you have a contraindication, unexplained bleeding, suspected pregnancy, or a clotting risk that has not been assessed.
Diane 35 is not intended as a general acne treatment when acne is mild or when no androgen-dependent features are present. It is also not suitable for women who need contraception alone without an androgen-related indication; the prescriber should select the most appropriate hormonal option for that purpose.
Diane 35 can cause unwanted effects, and some require urgent medical attention. The most clinically significant concern is venous thromboembolism, which means a blood clot in a deep vein or a clot that travels to the lungs. Combined hormonal products containing ethinylestradiol are associated with this risk.
Possible adverse effects include:
Urgent symptoms include one-sided leg swelling or pain, sudden breathlessness, chest pain, coughing blood, fainting, severe abdominal pain, sudden vision loss, or a severe new headache. These symptoms may indicate thrombosis, stroke, pulmonary embolism, or another serious complication.
Diane 35 is not suitable for every woman. The risk of thrombosis rises with several factors combined, including smoking, prolonged immobility, previous clotting problems, some inherited thrombophilias, and certain migraine patterns. Medsafe safety communications for combined hormonal medicines emphasise assessment of individual clotting risk before treatment [4].
| Treatment approach | Main action | Main limitation |
|---|---|---|
| Diane 35 hormonal tablets | Reduces androgen signalling and ovarian androgen activity | Systemic clotting and hormonal risks require screening |
| Topical acne treatment | Acts directly on the skin | Does not address systemic androgen activity |
| Hair-removal methods | Removes visible hair | Does not reduce new androgen-stimulated growth |
| Specialist endocrine treatment | Targets a defined hormonal or metabolic cause | Requires diagnosis, monitoring, and individual selection |
Diane 35 may be preferred when acne or hirsutism is linked to androgen excess and topical treatment has not provided adequate control. A topical approach may be preferable when symptoms are limited to the skin and systemic hormones are unsuitable. Hair-removal methods can be useful alongside medical treatment because existing coarse hairs do not disappear immediately when androgen activity falls.
In clinical practice, doctors usually set expectations around months rather than days. Acne often improves before hirsutism, while coarse facial hair may need additional cosmetic treatment during the early phase.
A clinician will usually ask about migraines, smoking, previous clots, recent surgery, immobilisation, blood pressure, liver disease, and family history. These questions are not routine formality; they help identify people for whom oestrogen-containing treatment may carry unacceptable risk.
Doctors also look for the cause of sudden androgenization. Rapid onset of severe hirsutism, deepening voice, marked muscle changes, or rapidly worsening acne can require investigation for an underlying endocrine disorder rather than routine treatment alone.
Diane 35 should be swallowed in the form prescribed, rather than split, crushed, or chewed without a specific instruction. Medsafe information from 2021 supports taking oral hormonal tablets according to the authorised administration directions because altering a tablet can affect accurate dosing or make it harder to follow the regimen. A pharmacist or prescriber can confirm whether a particular tablet may be divided when swallowing is difficult. Do not compensate for an altered or missed tablet by taking extra doses independently. Ask a pharmacist for advice if swallowing the tablet is difficult.
Headache is a recognised possible adverse effect of combined hormonal treatment, according to EMA safety information published in 2013. A new severe headache, migraine with aura, visual disturbance, weakness, speech difficulty, or numbness requires urgent medical assessment because these symptoms can indicate a serious vascular or neurological problem. Women with migraine with aura should not start Diane 35 unless a specialist has established an appropriate alternative plan. Ordinary mild headaches should still be reported if they become persistent or change pattern.
Some medicines and supplements can reduce hormonal exposure or alter safety, as described in Medsafe guidance from 2021. Important examples include enzyme-inducing epilepsy medicines, some tuberculosis treatments, certain HIV medicines, and St John’s wort. Some antiviral treatments can also change ethinylestradiol exposure. Give the prescriber a complete list before starting, including non-prescription products and herbal supplements.
Diane 35 should not be used during pregnancy, and pregnancy should be discussed promptly if it occurs during treatment. EMA safety information from 2013 identifies pregnancy as a reason to stop exposure and reassess the treatment plan. Breastfeeding also requires individual assessment because hormonal components may affect milk production or expose the infant through breast milk. A clinician should select an appropriate alternative when pregnancy is planned, suspected, or confirmed.
A previous venous thromboembolism is one clear condition that can rule out Diane 35, based on WHO medical eligibility guidance published in 2015. Other exclusions include migraine with aura, severe liver disease, certain cancers, and uncontrolled hypertension. A family history of early thrombosis may also require investigation before prescribing. The decision depends on the complete risk profile rather than one isolated symptom.
Sudden shortness of breath, chest pain, coughing blood, one-sided leg swelling, severe abdominal pain, sudden vision loss, or new neurological symptoms require urgent medical attention. Medsafe safety information from 2021 identifies these symptoms as possible warning signs of serious complications associated with combined hormonal treatment. Severe allergic swelling or difficulty breathing also requires emergency care. Do not take another dose while urgent medical advice is being obtained if a serious reaction or clot symptom is suspected.
Lack of improvement should lead to a clinical review rather than an increased dose. Dermatology and endocrine guidance available through the EMA in 2013 recognises that acne, hirsutism, and androgen-related symptoms respond at different speeds. Persistent symptoms may reflect another cause, inadequate treatment duration, missed doses, or a condition such as PCOS requiring broader management. A prescriber can reassess the diagnosis, review interactions, and decide whether Diane 35 remains suitable.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
My jawline acne gradually settled, and my skin became less oily. The first few weeks brought nausea and breast tenderness, but those symptoms eased. I found the tablet easier to remember when I took it with my evening routine.
Pukekohe Several months 6 Nov 2026I had been troubled by facial hair and irregular bleeding earlier in life. The treatment helped the skin symptoms, but headaches became more frequent, so my doctor reviewed the prescription. I stopped after that review rather than changing the schedule myself.
Palmerston North Not mentioned 8 Oct 2026By the second month, fewer deep spots appeared around my chin. I still needed a topical product for individual breakouts. Mood changes were noticeable at first and were the main drawback for me.
Hastings By the second month 16 Oct 2026The improvement in new growth was slow, and I continued hair removal during treatment. After several months, the hair seemed finer. Missing tablets made the routine stressful, so I used a daily reminder.
Queenstown Several months 26 Oct 2026My cycles became more predictable and my skin improved. I disliked the breast tenderness and occasional nausea, especially early on. The benefits were meaningful, but regular medical review remained part of the treatment.
Timaru Not mentioned 2 Nov 2026
